DCM Shriram Fine Chemicals Limited (NSE: DSFCL, BSE: 544703) is a #INVALID COMPANY ID-based company in the Pharmaceutical Intermediates industry. With a market capitalisation of ₹228 Cr, it ranks #2,489 by market cap among the 6,197 Indian listed companies on FinBizNet, and #1 of 4 in Pharmaceutical Intermediates. At ₹27.45 (as of 10 Nov 2026), the share price is 47.7% below its 52-week high of ₹52.50 and 58.9% above its 52-week low of ₹17.28.
| Current Price | ₹27.45 |
|---|---|
| Market Cap | ₹228 Cr |
| NSE Symbol | DSFCL |
| BSE Code | 544703 |
| Sector | Materials > Chemicals > Speciality Chemicals |
| Sub-Industry | Specialty Chemicals > Pharmaceutical Intermediates |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -1.67% |
| Return on Assets | -0.31% |
| 52-Week Range | ₹17.28 – ₹52.50 |
| 3-Month Price Change | +9.0% |
| Beta (1Y) | 1.28 |
| Dividend Yield | 1.52% |
| Headquarters | #INVALID COMPANY ID |
| Website | dsfcl.com |
| Revenue | ₹91 Cr |
|---|---|
| Net Profit | ₹3 Cr |
| Net Margin | 2.9% |
| EPS (Basic) | ₹0.30 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
DCM Shriram Fine Chemicals Limited reported revenue of ₹91 Cr in Q1 FY27, down 2.5% from ₹93 Cr in Q4 FY26. It posted a net profit of ₹3 Cr for the quarter, against a net loss of ₹4 Cr in Q4 FY26.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q1 FY27 | ₹91 Cr | ₹3 Cr | 2.9% |
| Q4 FY26 | ₹93 Cr | −₹4 Cr | −4.1% |
| Q3 FY26 | ₹97 Cr | −₹1 Cr | −1.5% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 50.11% of DCM Shriram Fine Chemicals Limited's shares as of Sept 2026, unchanged from Dec 2025. Delivery averaged 76.4% of traded volume across 5 NSE sessions (3 Nov 2026 – 9 Nov 2026).
DCM Shriram Fine Chemicals Limited engages in the manufacturing and selling of chemical products and intermediates in India and internationally. Its Pharma products includes D (-) alpha phenyl glycine base, D (-) alpha phenyl glycine ethyl potassium dane salt, D (-) alpha phenyl glycine chloride hydrochloride, D (-) para hydroxy phenyl glycine base, D (-) para hydroxy phenyl glycine methyl potassium dane salt, D (-) para hydroxy phenyl glycine methyl ester, DL 2-(2-Chloro Phenyl) glycine, valine hydantoin, sodium phenoxy acetate, phenoxy acetic acid, phenyl acetic acid, potassium phenyl acetate, sodium phenyl acetate, benzaldehyde, benzyl chloride, benzyl alcohol, benzyl benzoate, benzyl cyanide, ortho chloro benzaldehyde, ortho chloro benzoic acid, ortho chloro benzyl cyanide, ortho chloro phenyl acetic acid, para chloro benzaldehyde, para chloro benzoic acid, para chloro benzyl cyanide, and D(-) phenyl glycine methyl ester hydrochloride; Agrochemical products include benzaldehyde, be
1. Manufacturing Chemicals Products-NA 2. NA-NA 3. NA-NA 4. NA-NA
1. Manufacturing Chemicals Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| DCM Shriram Fine Chemicals Limited | ₹228 Cr | n/m | -1.67% | ₹91 Cr | — |
| Samrat Pharmachem Ltd. | ₹82 Cr | n/m | -4.73% | ₹80 Cr | -11.5% |
| Eiko Lifesciences Ltd | ₹71 Cr | 15.4 | 8.40% | — | -12.6% |
| Caprolactam Chemicals Ltd. | ₹21 Cr | 12 | 30.87% | ₹0 Cr | +1.9% |
Listed by market capitalisation. Ratios are shown for context only.
DCM Shriram Fine Chemicals Limited is trading at ₹27.45, with a market capitalisation of ₹228 Cr.
DCM Shriram Fine Chemicals Limited operates in the Materials > Chemicals > Speciality Chemicals space (Specialty Chemicals > Pharmaceutical Intermediates).
DCM Shriram Fine Chemicals Limited has a return on equity of -1.67%.
DCM Shriram Fine Chemicals Limited is listed on the NSE under the symbol DSFCL and on the BSE under the scrip code 544703.
In Q1 FY27, DCM Shriram Fine Chemicals Limited reported revenue of ₹91 Cr and net profit of ₹3 Cr, with basic EPS of ₹0.3 (consolidated, parsed from the company's exchange filing).
Promoters held 50.11% of DCM Shriram Fine Chemicals Limited's shares as of Sept 2026, unchanged from Dec 2025.
Data as of 10 Nov 2026. Descriptive market data only — not investment advice.